Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2020 | LB-100 in low and intermediate risk MDS

Rami Komrokji, MD, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, explores the rationale and trial design of a Phase I study evaluating LB-100, a phosphatase inhibitor, in low and intermediate-risk myelodysplastic syndrome (MDS) patients with or without deletion 5q, a common genetic abnormality in MDS. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).